ID - 765
DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY
T Facona, S Zweegmanb, V Hungriac, NJ Bahlisd, CP Vennere, M Braunsteinf, L Pourg, J Martih, A Maiolinoi, SZ Usmanij
a University of Lille, CHU Lille, Lille, France
b Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
c Clínica Médica São Germano, São Paulo, Brazil
d Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada
e Cross Cancer Institute, University of Alberta, Edmonton, Canada
f Perlmutter Cancer Center, NYU Langone Health, New York, United States
g University Hospital Brno, Czech Republic
h Hospital Universitario Mútua de Terrassa, Spain - Spain
i Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil
j Memorial Sloan Kettering Cancer Center, New York, United States
Ver más
